In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors
- 1 September 2000
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 109 (2) , 155-163
- https://doi.org/10.1016/s0165-5728(00)00307-6
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- SR141716A, a potent and selective antagonist of the brain cannabinoid receptorPublished by Wiley ,2001
- Relative involvement of cannabinoid CB1 and CB2 receptors in the Δ9-tetrahydrocannabinol-induced inhibition of natural killer activityEuropean Journal of Pharmacology, 2000
- Immune function alterations in mice tolerant to Δ9-tetrahydrocannabinol: functional and biochemical parametersJournal of Neuroimmunology, 1998
- Opiates Transdeactivate Chemokine Receptors: δ and μ Opiate Receptor–mediated Heterologous DesensitizationThe Journal of Experimental Medicine, 1998
- SR141716A is an inverse agonist at the human cannabinoid CB1 receptorEuropean Journal of Pharmacology, 1997
- Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesisLife Sciences, 1997
- In vivo and in vitro clomipramine treatment decreases the migration of macrophages in the ratEuropean Journal of Pharmacology, 1997
- The N-formyl peptide receptor: A model for the study of chemoattractant receptor structure and functionPharmacology & Therapeutics, 1997
- Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte SubpopulationsEuropean Journal of Biochemistry, 1995
- Phospholipase participation in cannabinoid-induced release of free arachidonic acidBiochemical Pharmacology, 1994